ADVANZ PHARMA Corp. Limited

Just ahead of Alvotech publishing its annual results, the biosimilars developer has revealed a first filing for its AVT23 proposed biosimilar to Xolair (omalizumab). In conjunction with partner Advanz

The European Medicines Agency has begun reviewing for potential pan-EU marketing approval 10 new products, including depemokimab, GSK’s IL-5 inhibitor that could become the first ultra-long-acting dru

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Zhifei Commits To Acquiring $2.93bn Of

The US Food and Drug Administration is once again warning about an increased risk of serious liver injury with Intercept ’s primary biliary cholangitis treatment Ocaliva (obeticholic acid) in a safet